Caissargues, July 6, 2023
Groupe Bastide announced today that it has finalized two small acquisitions, one strengthening its Perfusion business in France and the other extending the Group's geographic footprint to the Dutch market.
Deepening of regional coverage in the Perfusion segment
Groupe Bastide has acquired 100% of the share capital of Occit'perf, a regional player operating in the Languedoc-Roussillon and Provence-Alpes-Côte d'Azur regions, specializing in infusion therapy and artificial enteral and parenteral nutrition. In 2022, Occit'perf generated revenue of €0.6 million with profitability in line with Group levels. The company will be consolidated from July 1, 2023. The acquisition will strengthen Groupe Bastide's regional presence in the highly dynamic Perfusion segment, which is growing at a rate of more than 10%.
Expansion into the Netherlands in online sales of respiratory care equipment
Bastide is entering the Netherlands with the acquisition of the Dutch company Oxigo, specialized in consulting and online sales of oxygen therapy and respiratory care equipment in Europe. The acquisition will expand Groupe Bastide's geographic presence in the Netherlands, in the fast-growing respiratory care segment. In 2022, Oxigo generated revenue of €0.7 million with profitability in line with Group levels. The company will be consolidated from July 1, 2023.
The two acquisitions finalized by which are fully in line with the Group's strategy of strengthening its international presence and developing high value-added activities, while keeping its debt ratios under control.
NEXT RESULTS:
2022-2023 revenue on Wednesday, August 30, 2023 after the close of trading
About Groupe Bastide Le Confort Médical
Created in 1977 by Guy Bastide, Groupe Bastide is a leading European provider of home healthcare services. Present in 7 countries, Bastide develops a permanent quality approach and is committed to providing medical devices and associated services that best meet patients' needs in key health areas: diabetes, nutrition, infusion, respiratory care, stomatherapy and urology. Bastide is listed on Euronext Paris (ISIN: FR0000035370, Reuters BATD.PA, - Bloomberg BLC: FP).
| Groupe Bastide | Actus Finance | |
| Vincent Bastide/Olivier Jourdanney T. +33 (0)4 66 38 68 08 www.bastide-groupe.fr | Analyst-Investor Hélène de Watteville T. +33 (0)1 53 67 36 33 | Press – Media Déborah Schwartz T. +33 (0)1 53 67 36 35 |